58 results about "Kynurenine" patented technology

The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.

This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3β kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.

The invention provides a bladder cancer diagnosis marker which comprises inosine, N-acetyl-N-2-formyl-5-methoxy kynurenine and phosphatidylserine (O-18: 0/0: 0). A diagnosis index for a low-level bladder cancer and a high-level bladder cancer can be built through combination of human serum inosine, N-acetyl-N-2-formyl-5-methoxy kynurenine and phosphatidylserine (O-18: 0/0: 0), and accurate and fast diagnosis is carried out on the bladder cancer. The invention further provides application of the bladder cancer diagnosis marker in preparation of the bladder cancer diagnosis kit. In addition, the invention further provides the bladder cancer diagnosis kit. The bladder cancer diagnosis marker is capable of accurately judging the bladder cancer and accurately distinguishing the low-level bladder cancer from the high-level bladder cancer; the accuracy of the diagnosis result is high; and the quantizable, objective and sensitive clinical diagnosis index is provided for diagnosis of the bladder cancer.

The invention belongs to the technical field of drug detection, and particularly relates to a method for directly determining three degradation products of tryptophan in a compound amino acid injection. The three degradation products of tryptophan refer to dioxindole alanine, kynurenine and 2-hydroxytryptophan. The method comprises the following specific steps: (1) preparing the following chromatographic conditions of a liquid chromatograph: a chromatographic column being an octadecylsilane chemically bonded silica chromatographic column; a mobile phase comprising a mobile phase A being a phosphate buffer solution and a mobile phase B being acetonitrile; the flow rate being 0.95-1.05 mL/min; the column temperature being 25-35 DEG C; the sample size being 5-100 [mu]L; gradient elution; andthe detection wavelength being 254 nm; (2) preparing a test solution; (3) preparing a reference substance solution; and (4) determining. The method has the advantages of strong specificity, high sensitivity and good repeatability, solves the technical problems of interference of other amino acid components in the prescription, inaccurate determination result caused by derivative reaction in otherdetection methods, and the like, and ensures the product quality.

The invention discloses a kit and a method for simultaneously detecting tryptophan and metabolites thereof in a biological sample based on ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), which belong to the technical field of UPLC-MS/MS detection. The kit comprises standard substances of tryptophan and metabolites of the tryptophan, and the tryptophan and the metabolites of the tryptophan comprise 3-hydroxyl kynurenine, 5-hydroxytryptamine, kynurenine, yellow uric acid, tryptophan, kynurenic acid, 3-hydroxyl o-aminobenzoic acid, 5-hydroxyl indoleacetic acid, 3-indoleacetic acid and 3-indolepropionic acid. According to the method, the tryptophan and the metabolites of the tryptophan are detected by utilizing UPLC-MS/MS, and a standard curve is established according to a peak area, so that the contents of the tryptophan and the metabolites of the tryptophan are obtained. The method for detecting the tryptophan and the metabolites of the tryptophan is simple to operate, has the characteristics of high sensitivity, good selectivity and the like, can accurately and quickly detect the tryptophan and the metabolites of the tryptophan at the same time, and has wide application value.

The invention relates to the technical field of biological medicine. The invention provides an immune polypeptide and application thereof, the immune polypeptide is obtained by connecting an end-capping group and a short peptide, and the short peptide is one or more of GFFY, GDFDFDY and DPPA-1. The immune polypeptide can be self-assembled to form a supramolecular nano-drug. After entering a tumor microenvironment, the supramolecular nano-drug can simultaneously reverse an immunosuppressive effect mediated by accumulation of metabolites such as excessive consumption of tryptophan and kynurenine in an IDO pathway; the nano-drug can be specifically combined with PD-L1 on the surface of cancer cells to block immune escape of tumor cells; meanwhile, the immune response of the organism is activated and enhanced, the three parts play a role in parallel, so that the organism generates strong immune response aiming at tumors, the optimal effect is achieved in cancer immunotherapy, and a new thought is provided for developing multifunctional tumor immunotherapy nano-drugs.

The invention belongs to the field of disease diagnostic kit, and more specifically relates to applications of a set of amino acid markers in preparation of an acute kidney injury (AKI) diagnostic agent or a kit. The amino acid marker is one or a composition of two selected from kynurenine, hippuric acid, and pidolic acid. The AUC values of the three amino acid markers in independent diagnosis ofacute kidney injury at acute renal injury early stage diagnosis are all larger than 0.7, the diagnosis distinguish effect is excellent. The diagnosis capacities of kynurenine and hippuric acid are better than that of clinically used renal function marker creatinine and early stage diagnosis marker NGAL; the diagnosis time of the above three amino acids on AKI is earlier than that of clinically used renal function marker urea nitrogen. The invention also provides a targeting amino acid metabonomic detection method capable of realizing quantitative analysis of a plurality of amino acids at the same time, the sensitivity is high, and the results are accurate and reliable.

The invention discloses a method for preparing kynurenine from horseshoe crab tails.The method comprises the following steps of preparation of dry horseshoe crab tail powder, preparation of horseshoe crab tail crude extract, primary separation and purification of the horseshoe crab tail crude extract, separation and purification of a component A8 and separation and purification of components A8-24, wherein separation and purification of the components A8-24 comprise the steps that an appropriate amount of components A8-24 are taken, methyl alcohol is added for dissolution, and normal phase column separation is conducted; 50 mg of samples are taken and stirred with 150 mg of silica gel powder, 5 g of silica gel is saturated with petroleum ether and then subjected to column packing, after the the samples are packed in a column, elution is conducted with petroleum ether and acetone, when the ratio of petroleum ether to acetone is 1:10, fractions are collected, the number of the fractions is 60, the fractions from the 25 tube to the 40 tube are merged, after the the fractions are merged, vacuum concentration is conducted, and after solvent is dried out, kynurenine is obtained.According to the method for preparing kynurenine from the horseshoe crab tails, kynurenine is separated from the horseshoe crab tails for the first time, and kynurenine serving as the active ingredient of the horseshoe crab tails has great significance in secondary development of horseshoe crab tails.

The invention relates to a hydrothorax microparticle metabolite combination, a kit and a method for diagnosing tuberculous pleurisy. The pleural effusion microparticle metabolite composition for diagnosing tuberculous pleurisy comprises phenylalanine, tyrosine, methionine, kynurenine, lauroyl carnitine, glycine-binding chenodeoxycholic acid, phosphatidylcholine with the ratio of 36: 7 and lysophosphatidylcholine with the ratio of 20: 2. The kit for diagnosing tuberculous pleurisy comprises an internal standard substance for detecting the concentration of metabolites in the pleural effusion microparticle sample extraction solution. A combined marker provided by the invention has the characteristics of high sensitivity and high specificity for the diagnosis of tuberculous pleurisy, at the same time, can be complementary with a traditional marker adenosine deaminase, and can be used for the auxiliary diagnosis of the tuberculous pleurisy by being combined with the traditional marker adenosine deaminase.

The invention relates to the field of biomedicine, and specifically to a diagnostic marker of a Parkinson's disease and application thereof. Up-regulated expression of kynurenine in the urine of a patient suffering from the Parkinson's disease is found for the first time, which suggests that the detection of expression level of the kynurenine has become one of the indicators for early diagnosis ofthe Parkinson's disease, thus confirming that the kynurenine can be used as a diagnostic marker of the Parkinson's disease, and providing a new direction for the diagnosis of the Parkinson's disease.

The invention belongs to the technical field of biological medicines, and particularly relates to an experimental method for rapidly detecting the activity of a human mesenchymal stem cell IDO1. The experimental method for rapidly detecting the activity of the human mesenchymal stem cell IDO1 comprises the following steps of: S1, culturing human mesenchymal stem cells; and S2, taking supernatant, and detecting the activity of indoleamine 2, 3-dioxygenase 1. By improving and optimizing a human mesenchymal stem cell culture method, the phenomena of cell adherence, quantity reduction and the like caused by high-density inoculation before cells are solved, so that the accuracy of a detection result is improved, and the accurate estimation and evaluation of the immune regulation and control function of the human mesenchymal stem cells are improved; and by determining a kynurenine solution, a trichloroacetic acid solution and a dimethylaminobenzaldehyde solution and selecting the mass concentration of the solutions, the evaluation accuracy of the function of the human mesenchymal stem cells is further improved.

A process for converting tryptophan into kynurenine. The conversion of tryptophan into kynurenine is carried out by irradiating a substance comprising tryptophan with electromagnetic radiation comprising waves with wavelength in the range of 10 nanometer to 750 nanometer.

The invention belongs to the technical field of medicinal chemistry. The invention discloses linear peptide or cyclic peptide with the tumor cell inhibition activity. The linear peptide or cyclic peptide contains condensation fragments of kynurenine and arginine. A mass spectrum rapid positioning method for selectively identifying a cyclic peptide compound containing the kynurenine in complex extract is further used for separating and obtaining a new cyclic peptide compound with the antitumor activity from phakellia fusca thiele; and full synthesis of the compound is realized by applying solid-phase synthesis, liquid-phase cyclization and ozonation strategies in the final stage.

The present invention addresses the problem of providing a novel therapeutic agent for an immune disease and a novel therapeutic agent for an anti-inflammatory agent. The present invention which can solve the problem is a mesenchymal stem cell characterized by being capable of producing kynurenine in a large amount or capable of secreting kynurenine in a large amount. The present invention also includes a mesenchymal stem cell which is characterized by being capable of producing kynurenine, which is synthesized from tryptophan with IDO induced in a cell by the treatment with IFNgamma, in a large amount or being capable of secreting the kynurenine in a large amount, and a mesenchymal stem cell which is characterized in that the JAK/STAT pathway thereof is enhanced in a steady state.

The invention provides a method, composition and kit for treating T-cell mediated diseases, degenerative joint diseases or diseases mediated by platelet activating factor (PAF) comprising administering to an animal in need thereof, an effective amount a pharmaceutical composition containing N-acetyl-kynurenine (NAK) or pharmaceutically acceptable salts thereof as the active ingredient.